Abstract
DNase/collagenase treatments are widely used to obtain single-cell suspensions of tumour cells and tumour-infiltrating T lymphocytes (TIL) from solid tumours. Since the functional integrity of such cells has been questioned, we have studied whether treatments with commonly used preparations of these enzymes could affect the expression of lymphocyte surface molecules and lymphocyte proliferative responsiveness. With peripheral-blood-derived T cells as a model, flow-cytometric analysis revealed strongly reduced expression of distinct CD molecules for each enzyme, notably CD2, CD4, CD8 and CD44 for DNase, and CD4, CD14, CD16, and CD56 for collagenase. The effects were found to be due to protease contaminations present in all but the purest enzyme preparations tested. Addition of serum or trypsin inhibitor abolished the effects. Since serum-free media are widely used to expand tumour-infiltrating T cells for clinical therapeutic use, data from early phenotypic analyses can be strongly misleading. Even after an 18-h rest period following the enzyme treatments, re-expression of the affected membrane markers was still far from complete. On the other hand, despite strongly reduced expression of CD2 molecules on the lymphocyte membrane, anti-CD2-induced proliferation was not affected, showing the redundancy of this signal molecule. Since other important T cell activation molecules (TCR, CD3, CD28) were not affected by enzymatic treatment, the use of expensive, highly purified collagenase/DNase preparations does not seem to be mandatory in clinical studies with expanded TIL.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Applegate KG, Balch CM, Pellis NR (1990) In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res 50: 7153
Baars JW, Fonk JCM, Scheper RJ, Blomberg-van der Flier BME von, Bril H, Valk P van de, Pinedo HM, Wagstaff J (1992) Treatment with tumour-infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study. Biotherapy 4: 289
Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8: 1858
De Jong R, Stokkers P, Lamme E, Kool JM, Borst F, Brouwer M, Miedema F, Van Lier RAW (1989) Regulation of T-cell differentiation by CD2 and CD28 accessory molecules. Immunology 67: 333
Feeney RE, Stevens FC, Osuga DT (1963) The specificities of chicken ovomucoid and ovoinhibitor. J Biol Chem 238: 1415
Hanna MG Jr, Peters LC (1978) Immunotherapy of established micrometastases withBacillus Calmette Guérin tumor cell vaccine. Cancer Res 38: 204
Hoover CH Jr, Surdyke GG, Dangel RB, Peters LC, Hanna MG Jr (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236
Knazek RA, Wu YW, Aebersold PM, Rosenberg SA (1990) Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. J Immunol Methods 127: 29
Leerling MF, Vaessen LMB, Reubsaet CHK, Weimar W, Ettekoven H, Marsman FR, Kreeftenberg JF (1990) Quality control of antihuman CD3 and CD4 monoclonal antibodies. Dev Biol Stand 71: 191
Lineweaver H, Murray W (1947) Identification of the trypsin inhibitor of egg white with ovomucoid. J Biol Chem 171: 565
Meuer CS, Hussey RE, Fabbi M, Fos D, Acuto O, Fitzgerald KA, Hodgdon JD, Protentis JP, Schlossman SF, Reinherz EL (1984) An alternative pathway of T-cell activation: a functional role for the 50 kD T11 sheep erythrocyte receptor protein. Cell 36: 897
Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Von Fliedner V (1988) Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogendriven stimulation despite T-cell receptor expression. Int J Cancer 42: 659
Newman I, Wilkinson PC (1992) Methods for phenotyping polarized and locomotor human lymphocytes. J Immunol Methods 147: 43
Peters LC, Brandhorst JS, Hanna MG Jr (1979) Preparation of immunotherapeutic antologous tumor cell vaccines from solid tumors. Cancer Res 39: 1353
Pichler WJ, Walker C, Wolff-Vorbeck G, Koponon M, Tax WJM, Weck AL de (1985) Characterization of T8 epitopes by enzymatic digestion, cross-blocking and involvement in cell-mediated lympholysis. Cell Immunol 96: 398
Riddell SR, Greenberg PD (1990) The use of antiCD3 and antiCD28 monoclonal antibodies to clone and expand human anti-gen-specific T-ceels. J Immunol Methods 128: 189
Rodrigues M, Nussenzweig RS, Romero P, Zavala F (1992) The in vivo cytotoxic activity of CD8+ T-cell clones correlates with their levels of expression of adhesion molecules. J Exp Med 175: 895
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318
Rothlein R, Dustin ML, Marlin SD, Springer TA (1986) A human intercellular adhesion molecule (ICAM-1) distinet from LFA-1. J Immunol 137: 1270
Sánchez-Madrid F, De Landázuri MO, Morago G, Cebrián M, Acevedo A, Bernabeu C (1986) VLA-3: a novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization. Eur J Immunol 16: 1343
Stoeck M, Miescher S, Qiao L, Capasso P, Barras C, Fliedner V von (1990) Stimulation of FACS-analyzed CD4+ and CD8+ human tumour-infiltrating lymphocytes with ionomycin + phorbol-12, 13-dibutyrate does not overcome their proliferative deficit. Clin Exp Immunol 79: 105
Sutherland DR, Abdullah KM, Cyopick P, Mellors A (1992) Cleavage of the cell-surfaceO-sialoglycoproteins CD34, CD43, CD44, and CD45 by a novel glycoprotease fromPasteurella haemolytica. J Immunol 148: 1458
Van Lier RAW, Brouwer M, Aarden LA (1988) Signals involved in T-cell activation. T-cell proliferation induced through the synergistic action of antiCD28 and antiCD2 monoclonal antibodies. Eur J Immunol 18: 167
Van Noesel C, Miedema F, Brouwer M, Rie MA de, Aarden LA, Van Lier RAW (1988) Regulatory properties of LFA-1 α and β chains in human T-lymphocyte activation. Nature 333: 850
Whiteside TL, Miescher S, Hurlimann J, Moretta S, Fliedner V von (1986) Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 37: 803
Vanelli JR (1991) The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. J Immunol Methods 139: 1
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mulder, W.M.C., Koenen, H., van de Muysenberg, A.J.C. et al. Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment. Cancer Immunol Immunother 38, 253–258 (1994). https://doi.org/10.1007/BF01533516
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01533516